Sangamo Biosciences (SGMO) Releases Earnings Results, Misses Expectations By $-0.14 EPS

Sangamo Biosciences (SGMO) reported quarterly earnings results on Wednesday, Aug-3-2016. The company reported $-0.38 earnings per share for the quarter, missing the analyst consensus estimate by $-0.14. Analysts had a consensus of $-0.24. The company posted revenue of $3.70 million in the period, compared to analysts expectations of $5.55 million. The company’s revenue was down -56.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.

Sangamo Biosciences closed down -0.04 points or -0.61% at $6.57 with 9,49,914 shares getting traded on Tusday. Post opening the session at $6.6, the shares hit an intraday low of $6.42 and an intraday high of $6.7 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on Jul 17, 2015, Edward O Ii Lanphier (President & CEO) sold 25,000 shares at $10.43 per share price. According to the SEC, on Jul 14, 2015, Henry Ward Wolff (Exec VP & CFO) sold 12,000 shares at $10.00 per share price. On Jun 9, 2015, Dale G Ando (VP, Therapeutic Dev. & CMO) sold 15,000 shares at $12.29 per share price, according to the Form-4 filing with the securities and exchange commission.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Company’s lead ZFP Therapeutic SB-728-T a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Company’s clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimer’s disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Sangamo Biosciences

Leave a Reply

Sangamo Biosciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sangamo Biosciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.